Improved outcome for children with acute lymphoblastic leukemia after risk-adjusted intensive therapy: A single-institution experience

Annals of Saudi Medicine

Volumn 28, Issue 4, 2008, Pages 251-259

  Al Nasser, Abdallah ^a   El Solh, Hassan ^a   De Vol, Edward ^a   El Hassan, Ibrahim ^a   Alzahrani, Ali ^a   Al Sudairy, Reem ^b   Al Mahr, Mohammed ^a   Al Musa, Abdulrahman ^a   Al Jefri, Abdulla ^a   Saleh, Mahasen ^a   Rifai, Samira ^a   Belgaumi, Asim ^a   Osman, Layla ^a   Ashraf, Khairy ^a   Salim, Mohammed ^a   Silo, Ameurfina ^c   Roberts, George ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER   (Saudi Arabia)

^c KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILD CARE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; INFANT; INTENSIVE CARE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RISK ASSESSMENT; RISK FACTOR; SAUDI ARABIA; SURVIVAL RATE; SURVIVAL TIME;

EID: 54349124603     PISSN: 02564947     EISSN: 13199226     Source Type: Journal    
DOI: 10.5144/0256-4947.2008.251     Document Type: Article

References (41)

1. Pui CH, Evans W. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-78.
2. Pui CH, Evans W. Acute lymphoblastic leukemic. N Engl J Med. 1998;339:605-15.
3. Ochs J, Mulhern R, Fairclough D, et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: A prospective study. J Clin Oncol. 1991;9:145-51.
4. Lipshultz S, Colan S, Gelber R, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-15.
5. Pui CH, Ribeiro R, Hancock M, et al. Acute myeloid leukemia in children treated with epipodophylotoxins for acute lymphoblastic leukemia. N Eng J Med. 1991;325:1682-7.
6. Rivera G, Raimondi S, Hancock M, et al. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational chemotherapy. Lancet. 1991;337:61-6.
7. Aur R, Sackey K, Sabbah R, et al. Combination therapy for childhood acute lymphocytic leukemia. The King Faisal Specialist Hospital Medical Journal. 1985;(2):79-89.
8. Kaplan E, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-81.
9. Roberts G, Aur R, Sheth K. Immunophenotypic and age patterns of childhood acute lymphoblastic leukemia in Saudi Arabia. Leukemia Research. 1990;14(7):667-672.
10. Khalil S, Qari M, Jackson J, et al. Immunophenotyping of childhood acute lymphoblastic leukemia in Saudi Arabia: Second Look. Leukemia Research. 1994;18(12):881-3.
11. Pui CH, Behm F, Crist W. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood. 1993;82:343-62.
12. Rivera G, Pinkel D, Simone J, et al. Treatment of acute lymphoblastic leukemia, 30 years' experience at St. Jude Children's Research Hospital. N Eng J Med. 1993;329:1289-95.
13. Konrad M, Metzler M, Panzer S, et al. Late relapses evolve from slow-responding subclones in t(12;21) - positive acute lymphoblastic leukemia: Evidence for the persistence of a preleukemic clone. Blood. 2003;101(9):3635-40.
14. Nachman J, Sather H, Sensel M, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic - leukemia and slow response to initial therapy. N Eng J Med. 1998;338:1663-71.
15. Nachman J, Sather H, Cherlow S, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group. J Clin Oncol. 1998;16(3):920-30.
16. Bhojwani D, Dong-Joon M, Raetz E, et al. New approaches to risk-adapted therapy for childhood acute lymphoblastic leukemia. ASH education program book, San Diego, California. 2003 Dec;6-9;102-8.
17. Sather H. Age at diagnosis in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986;14(3):166-72.
18. Crist W, Boyett J, Pullen J, et al. Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: a Pediatric Oncology Group review. Med Pediatr Oncol. 1986;14(3):135-9.
19. Smith M, Bleyer W, Crist W, et al. Uniform criteria for childhood acute lymphoblastic leukemia risk classification. J Clin Oncol. 1996;14(2):680-1.
20. Boissel N, Auclerc M-F, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21(51):774-80.
21. Uckun F, Gaynon P, Sensel M, et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: A Children's Cancer Group Study. J Clin Oncol. 1997;15(6):2214-21.
22. Gajjar A, Harrison P. Sandlund J, et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood. 2000;96(10):3381-4.
23. Burger B, Zimmermman M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia. Significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21(2):184-8.
24. Pui CH. Mahmoud H, Rivera G, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-5.
25. Conter V, Schrappe M, Arico M, et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. J Clin Oncol. 1997;15:2786-91.
26. Trueworthy R, Shuster J, Look T, et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group Study. J Clin Oncol. 1992;10(4):606-13.
27. Heerema N, Sather H, Sensel M, et al. Prognostic impact of trisomies of chromosome 10, 17 and 5 among children with high hyperdiploidy (>50 chromosomes). J Clin Oncol. 2000;18(9):1876-87.
28. Heerema N, Nachman J, Sather H, et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 1999;94(12):4036-45.
29. Rubnitz J, Look T. Molecular genetics of childhood leukemias. Pediatr Hematol Oncol. 1998;20(1):1-11.
30. Schrappe M, Reiter A, Zimmermann M, et al. Long term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Franfurt-Munster. Leukemia. 2000;14(12):2205-22.
31. Gajjar A, Ribeiro R, Hancock M, et al. Persistence of circulating blasts after 1 week of multi-agent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995;86(4):1292-5.
32. Donadieu J, Hill C. Early response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukemia: a methodological review. Br J Haematol. 2001;115(1):34-45.
33. Gaynon P, Desai A, Bostrom B, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer. 1997;801:1717-26.
34. Van Dongen J, Macintyre E, Gabret J, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-I concerted action: Investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901-28.
35. Cave H, Van der Werff ten Bosh J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Eng J Med. 1998;339(9):591-98.
36. Coustan-Smith E, Sancho J. Behm F, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100(1):52-8.
37. Moos P, Raetz E, Carlson M, et al. Identification of gene expression profiles that segregate patients with childhood leukemia. Clin Cancer Res. 2002;8(10):3118-30.
38. Yeoh E, Ross M, Shurtleff, et al. Classification, subtype discovery and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer cell. 2002;1(2):133-43.
39. Ross M, Zhou Y, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by expression profiling. Blood. 2003;102:2951-59.
40. Evans W, Crom W, Abromowitch M, et al. Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Eng J Med. 1986;314:471-7.
41. Evans W, Relling M, Rodman J, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Eng J Med. 1998;338:499-05.